VanEck Pharmaceutical ETF
PPH
60 hedge funds and large institutions have $157M invested in VanEck Pharmaceutical ETF in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 9 closing their positions.
3% less funds holding
Funds holding: 62 → 60 (-2)
5.59% less ownership
Funds ownership: 54.62% → 49.03% (-5.6%)
19% less capital invested
Capital invested by funds: $195M → $157M (-$37.5M)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.89M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$2.59M |
| 3 |
VF
Virtu Financial
New York
|
+$2.47M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.39M |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$505K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$7.47M |
| 2 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
-$7.2M |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$3.49M |
| 4 |
Morgan Stanley
New York
|
-$2.72M |
| 5 |
Jane Street
New York
|
-$2.06M |
PPH Hedge Fund Activity: Q3 2015 in Review
60 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2015, worth a combined $157M — down 19% from $195M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PPH and 7 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 16 added.
The largest buyer was Credit Suisse, adding an estimated $4.89M. The largest seller was Envestnet Asset Management, exiting entirely with an estimated $7.47M sold.
- 60 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2015, down from 62 in Q2 2015.
- Funds reported $157M of VanEck Pharmaceutical ETF stock for Q3 2015, down 19% quarter-over-quarter.
- 7 funds opened new VanEck Pharmaceutical ETF positions in Q3 2015 and 9 closed out, a net change of -2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2015 was Credit Suisse, an estimated $4.89M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2015 was Envestnet Asset Management, an estimated $7.47M sold.
Based on aggregated 13F filings for Q3 2015.